SCHEMBL18319348

SCHEMBL18319348

CN1C(=O)C(O)=NC(c2ccc(Cl)cc2)c2cc(Cl)ccc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.37
OPRK1 P41145 2/20 0.37
PDE3A Q14432 1/20 0.37
CHRM2 P08172 1/20 0.36
ADRA2A P08913 1/20 0.36
PDE4D Q08499 1/20 0.36
GAA P10253 1/20 0.34
TSPO P30536 1/20 0.34
CA2 P00918 3/20 0.34
CA12 O43570 2/20 0.34
CA9 Q16790 2/20 0.34
CA4 P22748 1/20 0.34
CA7 P43166 1/20 0.34
CA1 P00915 2/20 0.34
MDM2 Q00987 2/20 0.33
KDR P35968 1/20 0.33
WDR5 P61964 1/20 0.33
TP53 P04637 1/20 0.33
TSHR P16473 1/20 0.33
MEN1 O00255 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9704603 0.79 OPRK1 (0.42) LMNAOPRK1PDE3ACHRM2ADRA2A
SCHEMBL5222768 0.68 OPRK1 (0.39) LMNAOPRK1PDE3ACHRM2ADRA2A
Iodide SCHEMBL11461823 0.68 CHEK1 (0.37) LMNAOPRK1PDE3ACHRM2ADRA2A
SCHEMBL18319671 0.65 LMNA (0.41) LMNAOPRK1PDE4DGAATSPO
SCHEMBL11471916 0.65 MEN1 (0.35) LMNAOPRK1PDE3AMEN1KMT2A
SCHEMBL23892731 0.63 AADAT (0.42) LMNAOPRK1PDE3ACHRM2ADRA2A
SCHEMBL30600563 0.63 OPRK1 (0.44) LMNAOPRK1PDE3ACHRM2ADRA2A
SCHEMBL28701831 0.63 OPRK1 (0.44) LMNAOPRK1PDE3ACHRM2ADRA2A
SCHEMBL28470317 0.62 KMT2A (0.41) LMNAOPRK1CHRM2ADRA2APDE4D
SCHEMBL11361155 0.62 CHEK1 (0.43) KDRMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10702537-B2 Devices and methods of treating methamphetamine addiction and medical and behavioral consequences of methamphetamine use and of HIV infection BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2020-07-07 US disclosed
US-10561668-B1 Devices and methods of treating methamphetamine addiction and medical and behavioral consequences of methamphetamine use and of HIV infection BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY (US) 2020-02-18 US disclosed
US-20190224211-A1 DEVICES AND METHODS OF TREATING METHAMPHETAMINE ADDICTION AND MEDICAL AND BEHAVIORAL CONSEQUENCES OF METHAMPHETAMINE USE AND OF HIV INFECTION BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE 2019-07-25 US disclosed
US-10022383-B2 Devices and methods of treating methamphetamine addiction and medical and behavioral consequences of methamphetamine use and of HIV infection BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2018-07-17 US disclosed
US-20160367565-A1 DEVICES AND METHODS OF TREATING METHAMPHETAMINE ADDICTION AND MEDICAL AND BEHAVIORAL CONSEQUENCES OF METHAMPHETAMINE USE AND OF HIV INFECTION BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2016-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10022383-B2 Devices and methods of treating methamphetamine addiction and medical and behavioral consequences of methamphetamine use and of HIV infection TSPO, SLC18A2, SLC18A3 LMNA 4218/4885OPRK1 9/4885PDE3A 3218/4885
US-10561668-B1 Devices and methods of treating methamphetamine addiction and medical and behavioral consequences of methamphetamine use and of HIV infection TSPO, SLC18A2, SLC18A3 LMNA 4218/4885OPRK1 9/4885PDE3A 3218/4885
US-20160367565-A1 DEVICES AND METHODS OF TREATING METHAMPHETAMINE ADDICTION AND MEDICAL AND BEHAVIORAL CONSEQUENCES OF METHAMPHETAMINE USE AND OF HIV INFECTION TSPO, SLC18A2, SLC18A3 LMNA 4218/4885OPRK1 9/4885PDE3A 3218/4885
US-10702537-B2 Devices and methods of treating methamphetamine addiction and medical and behavioral consequences of methamphetamine use and of HIV infection TSPO, SLC18A2, SLC18A3 LMNA 4218/4885OPRK1 9/4885PDE3A 3218/4885
US-20190224211-A1 DEVICES AND METHODS OF TREATING METHAMPHETAMINE ADDICTION AND MEDICAL AND BEHAVIORAL CONSEQUENCES OF METHAMPHETAMINE USE AND OF HIV INFECTION TSPO, SLC18A2, SLC18A3 LMNA 4218/4885OPRK1 9/4885PDE3A 3218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.